However, we still see areas of weakness in the portfolio, including upcoming patent losses and a highly uncertain pipeline due to the complexities of running CNS trials. Historically, the firm ...

Festival holidays wind down, the production line at Nanyang Yaoyibao Mugwort Products Company (hereafter as Yaoyibao Company) in Nanyang, Central China's Henan Province, roars back to life. The air ...

BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...

Growth across the Manufacturing and RMS segments is likely to have contributed to Charles River's fourth-quarter revenues.

Central China's Henan Province, roars back to life. The air crackles with the celebratory boom of... at 03:53 Lundbeck's potential treatment amlenetug for Multiple System Atrophy receives Fast Track ...

SOM intends to advance the drug into a phase 2b trial later this year, and reckons it has key advantages over Lundbeck's Xenazine (tetrabenazine), a well-established VMAT2 inhibitor used to treat ...

RM has received research grant support from Stanley Medical Research Institute, CIHR/GACD/National Natural Science Foundation of China; speaker/consultation fees from Lundbeck, Janssen, Shire, Purdue, ...

She is currently a principal investigator, supported by the China Postdoctoral Science Foundation under ... and travel support from Lundbeck HK and Aculys Pharma, Japan, which are outside the ...

Lars Søren Rasmussen, Chair of Lundbeck’s Board of Directors, has decided not to seek re-election at the Annual General Meeting scheduled for March 26, 2025. Following the Annual General Meeting, ...

Investing.com -- Shares of Lundbeck dropped by 7% following the release of its fourth-quarter financial results, which revealed revenues falling short of consensus estimates. The Danish ...

China’s population has shrunk for three years in a row despite a slight increase in the birth rate last year. The working population, classified as those between the ages of 16 and 59, also ...

Neuroscience specialist Lundbeck has agreed to buy Longboard Pharmaceuticals for $2.6 billion, expanding its pipeline with an epilepsy drug tipped as a future blockbuster. The Danish drugmaker has ...